001     181419
005     20240301130857.0
024 7 _ |a 10.18383/j.tom.2017.00005
|2 doi
024 7 _ |a pmid:30042974
|2 pmid
024 7 _ |a pmc:PMC6024456
|2 pmc
024 7 _ |a 2379-1381
|2 ISSN
024 7 _ |a 2379-139X
|2 ISSN
037 _ _ |a DKFZ-2022-01987
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Straub, Sina
|0 P:(DE-He78)4e04dcea1b6a4449a8fa005bcf36322b
|b 0
|e First author
|u dkfz
245 _ _ |a Mask-Adapted Background Field Removal for Artifact Reduction in Quantitative Susceptibility Mapping of the Prostate.
260 _ _ |a Ann Arbor, Michigan
|c 2017
|b Grapho Publications
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1661330848_30652
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a We propose an alternative processing method for quantitative susceptibility mapping of the prostate that reduces artifacts and enables better visibility and quantification of calcifications and other lesions. Three-dimensional gradient-echo magnetic resonance data were obtained from 26 patients at 3 T who previously received a planning computed tomography of the prostate. Phase images were unwrapped using Laplacian-based phase unwrapping. The background field was removed with the V-SHARP method using tissue masks for the entire abdomen (Method 1) and masks that excluded bone and the rectum (Method 2). Susceptibility maps were calculated with the iLSQR method. The quality of susceptibility maps was assessed by one radiologist and two physicists who rated the data for visibility of lesions and data quality on a scale from 1 (poor) to 4 (good). The readers rated susceptibility maps computed with Method 2 to be, on average, better for visibility of lesions with a score of 2.9 ± 1.1 and image quality with a score of 2.8 ± 0.8 compared with maps computed with Method 1 (2.4 ± 1.2/2.3 ± 1.0). Regarding strong artifacts, these could be removed using adapted masks, and the susceptibility values seemed less biased by the artifacts. Thus, using an adapted mask for background field removal when calculating susceptibility maps of the prostate from phase data reduces artifacts and improves visibility of lesions.
536 _ _ |a 315 - Imaging and radiooncology (POF3-315)
|0 G:(DE-HGF)POF3-315
|c POF3-315
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a artifact reduction
|2 Other
650 _ 7 |a background field removal
|2 Other
650 _ 7 |a calcification
|2 Other
650 _ 7 |a prostate cancer
|2 Other
650 _ 7 |a quantitative susceptibility mapping
|2 Other
700 1 _ |a Emmerich, Julian
|0 P:(DE-He78)cb524d7857f62988258612fc095c2ae0
|b 1
700 1 _ |a Schlemmer, Heinz-Peter
|0 P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec
|b 2
|u dkfz
700 1 _ |a Maier-Hein, Klaus H
|0 P:(DE-He78)33c74005e1ce56f7025c4f6be15321b3
|b 3
|u dkfz
700 1 _ |a Ladd, Mark E
|0 P:(DE-He78)022611a2317e4de40fd912e0a72293a8
|b 4
|u dkfz
700 1 _ |a Röthke, Matthias
|0 P:(DE-He78)3d11afed6b72f876ad1bba9418e30dac
|b 5
700 1 _ |a Bonekamp, David
|0 P:(DE-He78)ea098e4d78abeb63afaf8c25ec6d6d93
|b 6
|u dkfz
700 1 _ |a Laun, Frederik
|0 P:(DE-He78)b709e6df1ec6b63e5ffad4c8131f6f4d
|b 7
|e Last author
773 _ _ |a 10.18383/j.tom.2017.00005
|g Vol. 3, no. 2, p. 96 - 100
|0 PERI:(DE-600)2857000-5
|n 2
|p 96 - 100
|t Tomography
|v 3
|y 2017
|x 2379-1381
909 C O |o oai:inrepo02.dkfz.de:181419
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)4e04dcea1b6a4449a8fa005bcf36322b
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)cb524d7857f62988258612fc095c2ae0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)33c74005e1ce56f7025c4f6be15321b3
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)022611a2317e4de40fd912e0a72293a8
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)3d11afed6b72f876ad1bba9418e30dac
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)ea098e4d78abeb63afaf8c25ec6d6d93
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-He78)b709e6df1ec6b63e5ffad4c8131f6f4d
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-315
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Imaging and radiooncology
|x 0
914 1 _ |y 2017
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b TOMOGRAPHY : 2019
|d 2021-02-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2021-02-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2021-02-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2021-02-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2021-02-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2021-02-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-02-04
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-02-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2021-02-04
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2021-02-04
920 1 _ |0 I:(DE-He78)E020-20160331
|k E020
|l E020 Med. Physik in der Radiologie
|x 0
920 1 _ |0 I:(DE-He78)E010-20160331
|k E010
|l E010 Radiologie
|x 1
920 1 _ |0 I:(DE-He78)E132-20160331
|k E132
|l Medizinische Bildverarbeitung
|x 2
920 1 _ |0 I:(DE-He78)E230-20160331
|k E230
|l E230 Medizinische Bildverarbeitung
|x 3
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)E020-20160331
980 _ _ |a I:(DE-He78)E010-20160331
980 _ _ |a I:(DE-He78)E132-20160331
980 _ _ |a I:(DE-He78)E230-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21